Neeraj Agarwal, MD, FASCO

Medical Oncologist @DanaFarber ; Co-director, Prostate Cancer Program @Harvard Cancer Consortium; EIC @ASCO Daily News, FCOI

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Truly humbled by the support of colleagues across the American Society of Clinical Oncology (@ASCO) global community. Thank you for the trust and encouragement—I’m deeply grateful and excited to serve. @OncoAlert @urotoday @OncBrothers @montypal @DrChoueiri @DrRanaMcKay

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit https://t.co/4riSVk7AQy to learn more about the candidates and place your vote! Thank you!!

[Neeraj Agarwal, MD, FASCO @neerajaiims]

In the #uromigoslive 👉discussion on the 👉potentially practice changing trials in #bladdercancer MIBC & 1st line metastatic setting👇 @Uromigos @brian_rini @tompowles1 @MattGalsky @PGrivasMDPhD @DrRosenbergMSK @shilpaonc @OncoAlert

[Dra. María Natalia Gandur Quiroga @nataliagandur]

⭐🟠 #UromigosLive 2026 | Nashville 🇺🇸

🔥 BLADDER PRESERVATION: ARE WE READY TO CHALLENGE THE NEED FOR CYSTECTOMY?

🎙️ @OncoAlert | @tompowles1 keeps the debate lively with @JoshMeeks @kalasri3 @PGrivasMDPhD & Anna Wilkins!

🔬 ADCs + PD-1 INHIBITION: A NEW FRONTIER?

✅ EV + pembrolizumab delivers impressive pCR rates.

🔎 But can we reliably define clinical complete response?

🔹 Cystoscopy and biopsies
🔹 MRI and urine cytology
🔹 ctDNA and utDNA
🔹 Long-term oncologic safety

🚀 EV-209 and other phase II studies are exploring bladder-sparing strategies.

💡 MY CLINICAL PEARL:
Achieving pCR is not the same as proving that cystectomy can safely be omitted.

🎯 The challenge is selecting the right patients without compromising cure.

🔥 Sharp questions, different viewpoints, clever answers and outstanding scientific exchange!

@Uromigos @tompowles1 @brian_rini @MattGalsky @MichvdHeijden @shilpaonc @DrRosenbergMSK @yao_zhu_sh @AttardLab @dr_coops @NehaVapiwala @TDorffOnc @neerajaiims @lalaniMD @DrKarieRuncie @TiansterZhang @MVossMD @montypal @HHammersMD @AlbigesL @ViktorGruenwald

#UroVoices #BladderCancer #GUOnc

[Neeraj Agarwal, MD, FASCO @neerajaiims]

Just in👉 @FDA approves durvalumab + enfortumab vedotin-ejfv for muscle invasive bladder cancer today based on ph3 Volga trial👇 Link👉 https://t.co/4YfCHFPrLp Comparison of EV+pembro vs EV+Durvalumab at the #UromigosLIVE meeting👇 @Uromigos @OncoAlert

[Shilpa Gupta, MD, FASCO @shilpaonc]

Not at #UromigosLive ? Don't miss the live stream of exciting discussions in bladder cancer 👇👇@OncoAlert
@Uromigos @brian_rini @tompowles1 @MattGalsky @MichvdHeijden @uromigosjapan @LosUromigos @montypal @neerajaiims @PGrivasMDPhD

[OncoAlert @OncoAlert]

https://t.co/IjyHaMFLGJ

[Neeraj Agarwal, MD, FASCO @neerajaiims]

@UroDocAsh @UrologyWatchHQ Congratulations, Ashish @UroDocAsh . This recognition is the result of years of your hard work, intelligence, persistence, team work and leadership.

[Niklas Klümper @niklas_kluemper]

🦠 NECTIN4 is not only an ADC target—it is also a viral entry receptor!

Fascinating new study in @Nature showing that NECTIN4 mediates rubella virus entry into airway and placental cells.

And NECTIN4 is already known as an entry receptor for measles virus!

🎯 An intriguing biological connection: Viruses exploit cell-surface receptors to gain entry, while ADCs such as enfortumab vedotin rely on receptor binding and intracellular payload delivery.

Could NECTIN4’s role in viral entry offer clues to why it is such an effective ADC target?

Target expression is only part of the story. Receptor trafficking and internalization matter too! 🔬

https://t.co/K76RzdXnfk

@PTarantinoMD @raffcolo

@OncoAlert @weoncologists @urotoday @Uromigos

@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3

[Dana-Farber Lank Center for Genitourinary Oncology @DanaFarber_GU]

This month's Lank Center GU Seminar is presented by Dr. Marina Sharifi @marina_sharifi of @UWCarbone
on her work developing liquid biopsy to study the biology of and follow treatment response or resistance in #prostatecancer

[UroToday.com @urotoday]

TALAPRO-3 results and the role of upfront PARP inhibition in APMS #ProstateCancer. @AarmstrongDuke @DukeCancer joins @neerajaiims @huntsmancancer in this discussion on UroToday. TALAPRO-3 is a phase 3 trial adding talazoparib to ADT + enzalutamide in approximately 600 patients with HRR-mutated #mHSPC. #WatchNow on UroToday > https://t.co/xyJnU06Xn1

[Hemostasis Today @HemostasisToday]

Early Immune Responses to Androgen Deprivation Therapy and Coronary Plaque Progression - Avirup Guha (@avirupguha)

@ICOSociety @neerajaiims

https://t.co/G5nlvwXnHO

#HemostasisToday

[UroToday.com @urotoday]

Overall Survival Results from the CAPItello-281 Trial of Capivasertib in PTEN-Deficient #mHSPC. @fizazi_karim @GustaveRoussy joins @neerajaiims @DanaFarber to discuss updated CAPItello-281 data in PTEN-deficient metastatic hormone-sensitive prostate cancer, which screened 6,000 men and enrolled roughly 1,000 randomized to ADT + abiraterone with or without capivasertib. #WatchNow > https://t.co/lxNerhslek

[Neeraj Agarwal, MD, FASCO @neerajaiims]

@NazliDizman @ASCO @ASCOTECAG @montypal @DrChoueiri @AnaVManana @AmandaNizamMD @JasmineKambojMD @jrgralow @PGrivasMDPhD @DrYukselUrun @CharuAggarwalMD Congratulations Nazli!! @NazliDizman Amazing to see all your wonderful accomplishments at such an early stage of your career.

[Nazli Dizman @NazliDizman]

🤩Reflecting on the past 10 years as an @ASCO member, I’m grateful for this community!
🙏Honored to receive the FASCO designation! Such a privilege to give back and #volunteer alongside many amazing people for a cause so close to our hearts!

🙏 #ASCO @ASCOTECAG @IMG_Oncologists @montypal @DrChoueiri @OncBrothers @IvyLorena_Md @TiansterZhang @Noha_Soror @ASridharMD @royaryam @SPremji7866 @FernandoDiazMD1 @realbowtiedoc @Doctor_EZ @MazieTsangMD @christinemphmd @GlopesMd @ZiadBakouny @ziremozay @ADESAIONCMD @inimfonjackson @shilpaonc @AndreaNecchi @NarjustFlorezMD @BernabeCarolina @AyeshaButtMD @KarunNeupaneMD @JiazhangXing

[Canadian Urological Association @CanUrolAssoc]

Celebrating 20 years of Uro Oncology excellence in Atlantic Canada at #ACUOG26
under the leadership of @RicardoARendon @PGrivasMDPhD @neerajaiims @MikeSerzanMD
Thank you!
@TiffanyPizioli

[Mark Wildgust (he/him) @MAWildgust]

At #ESMO26 we introduced a new word, #RIPTAC, JNJ-6143. Introducing another innovation presented @sitcancer yesterday! FIH Investigational combo of Pasritamig our @JNJInnovMed KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 & signal 2 together! #MyCompany

[Shilpa Gupta, MD, FASCO @shilpaonc]

🇮🇳 Team India has entered the @Uromigos World Cup bringing spirit of innovation to tackle the issue of disparities and access. 🏆

☕ From Mumbai @adidhanawat to Cleveland, join us for Chai Pe Charcha as we explore low-dose immunotherapy and the potential to make bladder cancer care more accessible and affordable!

And what’s Team India without a little Bollywood magic? 🎶🚂 the music and please LIKE ❤️our video below and show us some love 🥰 👇👇👇

#UromigosLive @UroDocAsh
@achoud72 @VivekSubbiah @VedangMurthy @AgrimaMianMD @montypal @neerajaiims @Parminder1699 @sonpavde @scserendipity1 @DrAnshul_Gupta @Garg_H @drgaganprakash @RenuEapen @NehaVapiwala @RamalingamMD @VincentRK @batraatulonc @DrAmitJoshi_TMC @DrGauravNarula @RenoHemonc @PGrivasMDPhD @karima_oualla @crisbergerot @DrYukselUrun @IBCG_BladderCA @BrainTumorDoc @NVijayvergiaMD @NazliDizman @AparnaKamatMD

[Paulo G Bergerot @PauloBergerot]

#ExerciseOncology is moving beyond research into everyday #CancerCare

The challenge? Making exercise accessible and feasible for all patients

Some thoughts on bridging this gap:

https://t.co/P01MQo8upn

[UroToday.com @urotoday]

Real-World Data Explores Post-177Lu-PSMA-617 Therapies in Advanced #ProstateCancer.
What works after 177Lu-PSMA-617 in #mCRPC? @xiaoweimd joins @neerajaiims to discuss real-world PRECISION data in 442 patients: median PFS on the next therapy was 10.7 months with an ARPI and 7.2 months with a taxane. #WatchNow on UroToday > https://t.co/qpThfeg4Dd

[Canadian Urological Association @CanUrolAssoc]

SPECIAL EXPERT SESSION WITH INVITED SPEAKER! Join us for a free live session, streamed online, on PARP Inhibitors in Advanced Prostate Cancer. Register today through event page & reserve your spot:https://t.co/9cCQcF9luB look forward to seeing you live or online!
@neerajaiims

[Cristiane D Bergerot, PhD, FASCO @crisbergerot]

That time of year is here again! ⏰ How did it come around so fast? 😅 @ASCO

Time to start preparing those abstracts for #ASCO27!

📍 Chicago | June 4–8, 2027
📝 Abstract deadline: January 26, 2027

Looking forward to another exciting year of science, innovation & collaboration!